Patents by Inventor Richard Ornberg

Richard Ornberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Biomaterials modified with superoxide dismutase mimics
    Patent number: 7445641
    Abstract: The present invention relates to biomaterials modified with non-proteinaceous catalysts for the dismutation of superoxide, and processes for making such materials. This modification may be by covalent conjugation, copolymerization, or admixture of the non-proteinaceous catalysts with the biomaterial. The resulting modified biomaterials exhibit a marked decrease in inflammatory response and subsequent degradation when placed in contact with vertebrate biological systems.
    Type: Grant
    Filed: May 26, 2000
    Date of Patent: November 4, 2008
    Assignee: Pharmacia Corporation
    Inventors: Richard Ornberg, Kishore Udipi, Denis Forster, Dennis Riley, Bruce Thurmond, Susan Henke, Kerry Brethauer
  • Biopolymers modified with superoxide dismutase mimics
    Publication number: 20060089710
    Abstract: This invention provides modified biopolymers comprising biopolymers attached to at least one non-proteinaceous catalyst capable of dismutating superoxide in the biological system or precursor ligand thereof. The invention further provides pharmaceutical compositions comprising the modified biopolymer and therapeutic methods comprising administering the modified biopolymer to a subject in need thereof.
    Type: Application
    Filed: September 15, 2005
    Publication date: April 27, 2006
    Inventors: Richard Ornberg, Kishore Udipi, Denis Forster, Dennis Riley, Kenneth Thurmond, Susan Henke, Kerry Brethauer, Saikat Joardar
  • Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents
    Publication number: 20040204472
    Abstract: A method for preventing or treating obesity and obesity-related complications in a subject involves a monotherapy with a Cox-2 inhibitor or a combination therapy with a Cox-2 inhibitor and a conventional weight-loss agent. Also described are therapeutic compositions comprising a Cox-2 inhibitor and a conventional weight-loss agent. Pharmaceutical compositions and kits for implementing the present method are also described.
    Type: Application
    Filed: February 5, 2004
    Publication date: October 14, 2004
    Applicant: Pharmacia Corporation
    Inventors: Michael Briggs, Scott Hauser, Richard Ornberg, Alane Koki
  • Isolation and culture of adrenal medullary endothelial cells producing blood clotting factor VIII:C
    Patent number: 4670394
    Abstract: The present invention discloses a new line of endothelial cell of adrenal medullary origin capable of producing blood clotting Factor VIII:C. A method of isolating and culturing said cell line has also been disclosed. Factor VIII:C is useful in treating hemophilia.
    Type: Grant
    Filed: November 16, 1984
    Date of Patent: June 2, 1987
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Harvey B. Pollard, Richard Ornberg, Dipak Banerjee, Moussa Youdim, Peter Lelkes, Eli Heldman